Life Sciences Newsletter

Life Sciences in Review: September 2026

October 12, 2026

Key highlights from September:

  • Biotech markets pulled back sharply in September, with biotech down (8.6%), led by mid-cap (11.8%), small-cap (10.4%) and micro-cap (10.1%), while large pharma fell (4.2%) and the NBI was roughly flat at (0.1%); specialty pharma was the only sub-sector to gain (+4.1%), and year-to-date performance diverged, with large-cap biotech up 34.8% and mid-cap up only 2.8%
  • M&A activity slowed while licensing doubled, with 4 M&A and 32 licensing transactions announced (vs. 9 M&A and 16 licensing in August), compared to 6 M&A / 18 licensing in September 2025 and 4 M&A / 40 licensing in September 2024; Telix/ITM ($2.4bn) was the only M&A deal above $1bn, with Telix acquiring ITM-11 in GEP-NETs one month after an FDA Complete Response Letter that cited manufacturing rather than clinical data, for $1.65bn upfront (70% of total), leaving ITM shareholders with 23.7% of Telix
  • Large pharma drove licensing activity, with 14 transactions carrying potential consideration of $1bn or more, although deal values remained heavily milestone-weighted and concentrated among a handful of buyers; Novo Nordisk struck agreements with Hengrui (obesity – $2.6bn), Orbis Medicines ($1.4bn) and Nanexa ($1.3bn), while Roche / Genentech partnered with Atavistik ($2.0bn), Simcere Zaiming ($1.5bn), Earendil Labs ($1.5bn) and Dualitas ($1.0bn); China outbound licensing remained robust, with InnoCare / Eli Lilly ($3.4bn; 3% upfront), Hengrui / Novo Nordisk ($2.6bn; 12% upfront; WW ex-Greater China), Simcere Zaiming / Roche ($1.5bn; 5% upfront) and HUTCHMED / GSK ($1.3bn; 8% upfront; WW ex-Greater China) all exceeding $1bn
  • Biopharma IPO activity moderated to two offerings, ADARx and Electra, against a backlog of 9 companies publicly on file with the SEC, with results split: ADARx priced at the top of its range to raise $350mm (+13.8% T+1, +17.3% to date), while Electra priced at the midpoint to raise $325mm and has since fallen (25.0%)
  • Reverse mergers paired with concurrent PIPEs continue to serve as an alternative path to public capital, with Lisata/Marea Therapeutics (~$225mm private placement) and Aethlon/North Immunology ($180mm private placement) announced in September; legacy public shareholders retained only ~2-5% of each combined company, with PIPE investors taking ~38% of Lisata/Marea
  • Follow-on activity slowed significantly, with 7 priced deals raising ~$1.2bn (vs. 13 deals / $1.8bn in August), though the average file-to-offer discount narrowed to (3.9%) from (9.8%); private financings rebounded, with 24 deals raising ~$2.2bn (vs. 16 deals / $1.0bn), led by Enveda’s $311mm Series E at a $2.0bn post-money valuation, Encoded’s $275mm Series F, Solstice Oncology’s $225mm Series A and Biossil’s $153mm round led by OpenAI
  • September clinical readouts delivered several notable successes, including Kodiak’s tarcocimab and tabirafusp matching EYLEA in the Phase 3 DAYBREAK wet AMD trial (shares +178%), Vera’s TRUTAKNA reducing the risk of composite kidney disease progression by 76% in the Phase 3 ORIGIN 3 IgAN trial and Definium’s DT120 meeting all endpoints in the Phase 3 Panorama GAD trial, including a 5.1-point improvement in HAM-A versus placebo
  • Novartis faced a series of pipeline setbacks in September, with pelacarsen missing the Phase 3 Lp(a)HORIZON primary endpoint and del-desiran, the centerpiece of its $12.0bn Avidity acquisition, failing Phase 3 HARBOR in myotonic dystrophy type 1; shares declined ~12.5% following HARBOR, prompting Artisan Partners to call for board-level changes and stronger dealmaking oversight. Holds on eight rap-cel trials following three patient deaths and the subsequent discontinuation of lifonebart in ALS added to pipeline concerns, against a backdrop of ongoing generic erosion following Entresto’s U.S. loss of exclusivity
  • The FDA granted accelerated approval to AstraZeneca’s ETCAMAH (camizestrant) plus a CDK4/6 inhibitor for first-line treatment of ESR1-mutated HR+/HER2- advanced breast cancer, despite a negative advisory committee vote; supported by the 315-patient Phase 3 SERENA-6 trial, the approval establishes a ctDNA-guided treatment approach enabling therapy switching before radiographic progression and marks AstraZeneca’s tenth FDA approval of 2026 and fourth in breast cancer
  • China published a five-year plan for its pharmaceutical industry, issued jointly by ten government agencies including the Ministry of Industry and Information Technology, the National Development and Reform Commission and the National Medical Products Administration; it targets at least 25% of global first-in-class drugs by 2030 and aims for China to rank firmly among global leaders in biopharma R&D